Skip to main content
Top
Published in: World Journal of Urology 1/2020

01-01-2020 | Original Article

Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor

Authors: M. Ferro, G. Di Lorenzo, M. D. Vartolomei, D. Bruzzese, F. Cantiello, G. Lucarelli, G. Musi, S. Di Stasi, R. Hurle, G. Guazzoni, G. M. Busetto, A. Gabriele, F. Del Giudice, R. Damiano, F. Perri, S. Perdona, P. Verze, M. Borghesi, R. Schiavina, G. L. Almeida, P. Bove, E. Lima, R. Autorino, N. Crisan, A. R. Abu Farhan, M. Battaglia, G. I. Russo, Vincenzo Ieluzzi, G. Morgia, P. De Placido, D. Terracciano, A. Cimmino, L. Scafuri, V. Mirone, O. De Cobelli, S. Shariat, Guru Sonpavde, C. Buonerba

Published in: World Journal of Urology | Issue 1/2020

Login to get access

Abstract

Background

Basophils, eosinophils and monocytes may be involved in BCG-induced immune responses and be associated with outcomes of bladder cancer patients receiving intravesical BCG. Our objective was to explore the association of baseline counts of basophils, eosinophils and monocytes with outcomes of patients with high-grade T1 bladder cancer receiving a standard course of intravesical BCG.

Methods

We retrospectively reviewed medical records of patients with primary T1 HG/G3 bladder cancer. After re-TURBT, patients were treated with a 6-week course of intravesical BCG induction followed by intravesical BCG every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months from initiation of therapy The analysis of potential risk factors for recurrence, muscle invasion and cancer-specific and overall survival was performed using univariable Cox regression models. Those factors that presented, at univariate analysis, an association with the event at a liberal p < 0.1, have been selected for the development of a multivariable model.

Results

A total of 1045 patients with primary T1 HG/G3 were included. A total of 678 (64.9%) recurrences, 303 (29.0%) progressions and 150 (14.3%) deaths were observed during follow-up. Multivariate analysis showed that logarithmic transformation of basophils count was associated with a 30% increment in the hazard of recurrence per unit increase of logarithmic basophils count (HR 1.30; 95% confidence interval 1.09–1.54; p = 0.0026). Basophil count modeled by quartiles was also significantly associated with time to recurrence [second vs. lower quartile HR 1.42 (1.12–1.79); p = 0.003, third vs. lower quartile HR 1.26 (1.01–1.57); p = 0.041; upper vs. lower quartile HR 1.36 (1.1–1.68); p = 0.005]. The limitations of a retrospective study are applicable.

Conclusion

Baseline basophil count may predict recurrence in BCG-treated HG/G3 T1 bladder cancer patients. External validation is warranted.
Literature
2.
go back to reference Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A (2014) International variations in bladder cancer incidence and mortality. Eur Urol 66(1):59–73CrossRef Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A (2014) International variations in bladder cancer incidence and mortality. Eur Urol 66(1):59–73CrossRef
3.
go back to reference Di Lorenzo G, Federico P, De Placido S, Buonerba C (2015) Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: a systematic review. Crit Rev Oncol Hematol 96(3):534–541CrossRef Di Lorenzo G, Federico P, De Placido S, Buonerba C (2015) Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: a systematic review. Crit Rev Oncol Hematol 96(3):534–541CrossRef
4.
go back to reference Cambier S et al (2016) EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette–Guérin. Eur Urol 69(1):60–69CrossRef Cambier S et al (2016) EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette–Guérin. Eur Urol 69(1):60–69CrossRef
7.
go back to reference Kluth LA et al (2013) Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. J Urol 190(2):480–486CrossRef Kluth LA et al (2013) Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. J Urol 190(2):480–486CrossRef
8.
go back to reference Bolenz C et al (2010) Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU Int 106(4):493–499CrossRef Bolenz C et al (2010) Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU Int 106(4):493–499CrossRef
9.
go back to reference Vartolomei MD et al (2018) Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis. Urol Oncol Semin Orig Investig 36(9):389–399CrossRef Vartolomei MD et al (2018) Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis. Urol Oncol Semin Orig Investig 36(9):389–399CrossRef
10.
go back to reference Schemper M, Wakounig S, Heinze G (2009) The estimation of average hazard ratios by weighted Cox regression. Stat Med 28(19):2473–2489CrossRef Schemper M, Wakounig S, Heinze G (2009) The estimation of average hazard ratios by weighted Cox regression. Stat Med 28(19):2473–2489CrossRef
11.
go back to reference Lucey DR, Clerici M, Shearer GM (1996) Type 1, and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9(4):532–562CrossRef Lucey DR, Clerici M, Shearer GM (1996) Type 1, and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9(4):532–562CrossRef
12.
go back to reference Thanhäuser A et al (1995) The induction of bacillus-Calmette–Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 40(2):103–108CrossRef Thanhäuser A et al (1995) The induction of bacillus-Calmette–Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 40(2):103–108CrossRef
13.
go back to reference Saint F et al (2002) Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette–Guerin treatment for superficial bladder cancer. J Urol 167(1):364–367CrossRef Saint F et al (2002) Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette–Guerin treatment for superficial bladder cancer. J Urol 167(1):364–367CrossRef
14.
go back to reference Luo Y, Chen X, O’Donnell MA (2003) Role of Th1 and Th2 cytokines in BCG-induced IFN-γ production: cytokine promotion and simulation of BCG effect. Cytokine 21(1):17–26CrossRef Luo Y, Chen X, O’Donnell MA (2003) Role of Th1 and Th2 cytokines in BCG-induced IFN-γ production: cytokine promotion and simulation of BCG effect. Cytokine 21(1):17–26CrossRef
15.
go back to reference Riemensberger J, Böhle A, Brandau S (2002) IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 127(1):20–26CrossRef Riemensberger J, Böhle A, Brandau S (2002) IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 127(1):20–26CrossRef
16.
go back to reference Saint F et al (2003) Urinary IL-2 assay for monitoring intravesical bacillus Calmette–Guérin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer 107(3):434–440CrossRef Saint F et al (2003) Urinary IL-2 assay for monitoring intravesical bacillus Calmette–Guérin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer 107(3):434–440CrossRef
17.
go back to reference Voehringer D (2017) Recent advances in understanding basophil functions in vivo. F1000Research 6:1464CrossRef Voehringer D (2017) Recent advances in understanding basophil functions in vivo. F1000Research 6:1464CrossRef
19.
go back to reference Tang H et al (2010) The T helper type 2 response to cysteine proteases requires dendritic cell-basophil cooperation via ROS-mediated signaling. Nat Immunol 11(7):608–617CrossRef Tang H et al (2010) The T helper type 2 response to cysteine proteases requires dendritic cell-basophil cooperation via ROS-mediated signaling. Nat Immunol 11(7):608–617CrossRef
20.
go back to reference Karasuyama H, Mukai K, Obata K, Tsujimura Y, Wada T (2011) Nonredundant roles of basophils in immunity. Annu Rev Immunol 29(1):45–69CrossRef Karasuyama H, Mukai K, Obata K, Tsujimura Y, Wada T (2011) Nonredundant roles of basophils in immunity. Annu Rev Immunol 29(1):45–69CrossRef
21.
go back to reference De Monte L et al (2016) Basophil recruitment into tumor-draining lymph nodes correlates with Th2 inflammation and reduced survival in pancreatic cancer patients. Cancer Res 76(7):1792–1803CrossRef De Monte L et al (2016) Basophil recruitment into tumor-draining lymph nodes correlates with Th2 inflammation and reduced survival in pancreatic cancer patients. Cancer Res 76(7):1792–1803CrossRef
22.
go back to reference De Monte L et al (2011) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208(3):469–478CrossRef De Monte L et al (2011) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208(3):469–478CrossRef
23.
go back to reference Mitre E, Nutman TB (2006) Basophils, basophilia and helminth infections. Chem Immunol Allergy 90:141–156PubMed Mitre E, Nutman TB (2006) Basophils, basophilia and helminth infections. Chem Immunol Allergy 90:141–156PubMed
24.
go back to reference Hart TK et al (2002) Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 130(1):93–100CrossRef Hart TK et al (2002) Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 130(1):93–100CrossRef
25.
go back to reference Borish LC et al (1999) Interleukin-4 receptor in moderate atopic asthma: a phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 160(6):1816–1823CrossRef Borish LC et al (1999) Interleukin-4 receptor in moderate atopic asthma: a phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 160(6):1816–1823CrossRef
26.
go back to reference Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M (2007) Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370(9596):1422–1431CrossRef Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M (2007) Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370(9596):1422–1431CrossRef
Metadata
Title
Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor
Authors
M. Ferro
G. Di Lorenzo
M. D. Vartolomei
D. Bruzzese
F. Cantiello
G. Lucarelli
G. Musi
S. Di Stasi
R. Hurle
G. Guazzoni
G. M. Busetto
A. Gabriele
F. Del Giudice
R. Damiano
F. Perri
S. Perdona
P. Verze
M. Borghesi
R. Schiavina
G. L. Almeida
P. Bove
E. Lima
R. Autorino
N. Crisan
A. R. Abu Farhan
M. Battaglia
G. I. Russo
Vincenzo Ieluzzi
G. Morgia
P. De Placido
D. Terracciano
A. Cimmino
L. Scafuri
V. Mirone
O. De Cobelli
S. Shariat
Guru Sonpavde
C. Buonerba
Publication date
01-01-2020
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 1/2020
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-02754-2

Other articles of this Issue 1/2020

World Journal of Urology 1/2020 Go to the issue